Evaluate Safety and Efficacy of ABT-335 in Combination With Rosuvastatin Calcium in Subjects With Multiple Abnormal Lipid Levels in the Blood

PHASE3CompletedINTERVENTIONAL

Enrollment

1,445

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

December 31, 2006

Conditions

DyslipidemiaCoronary Heart DiseaseMixed Dyslipidemia

Interventions

DRUG

ABT-335

135 mg, daily, 12 weeks

DRUG

Rosuvastatin Calcium

Daily, 12 weeks, see Arm Description for dosage information

DRUG

Placebo

Daily, 12 weeks, see Arm Description for information regarding placebo type

Trial Locations (1)

Global Medical Information, North Chicago